Post-intervention and follow-up effects for parental/carer outcomes
| Parental outcome | Post-treatment effect | Heterogeneity statistics | Outlier detection (Y/N) | Presence of influential studies (Y/N) | Egger’s test | Quality based on EPHPP |
| Post-treatment effects | ||||||
| Anxiety (n=5)39 42 45 46 | d=−0.11 (95% CI −0.35, 0.13, p=0.27) | τ2=0 (95% CI 0.00, 0.28), I 2=0%, 95% PI=−0.50, 0.27 | N | N | β=−0.86 (95% CI −3.88, 2.15, p=0.61) | Strong45 46
Moderate39 Weak42 |
| Anxiety between-group only (n=4)39 45 46 | g=−0.14 (95% CI −0.52, 0.24, p=0.33) | τ2=0.00 (95% CI 0.00, 0.70, I 2=0%, 95% PI=−0.79, 0.51 | N | Y | β=−0.93 (95% CI −7.09, 5.32, p=0.80) | Strong45 46
Moderate39 Weak |
| Depression (n=6)41 42 45 46 50 | d=0.22 (95% −0.24, 0.68, p=0.28) | τ2=0.10 (0.00, 1.21), I 2=59.4%, 95% PI=−0.79, 1.23 | N | Y | β=6.06 (95% −10.46, 2.69, p=0.52) | Strong45 46
Moderate41 50 Weak42 |
| Depression between-group only (n=4)41 45 46 | g=0.41 (95% CI −0.28, 1.10, p=0.16) | τ2=0.10 (95% CI 0.00, 2.70), I 2=54%, 95% PI=−1.23, 2.05 | N | Y | β=8.56 (95% CI 1.05, 16.05, p=0.16) | Strong45 46
Moderate41 Weak |
| Stress (n=5)42 45 46 51 | d=−0.04 (95% CI −0.46, 0.38, p=0.80) | τ2=0.05 (95% CI 0.00, 0.88), I 2=39.5%, 95% PI=−0.89, 0.81 | N | Y | β=5.05 (95% CI −0.37, 10.47, p=0.17) | Strong45 46
Moderate51 Weak42 |
| Stress between-group only (n=3)45 46 | d=0.23 (95% CI −0.04, 0.49, p=0.07) | τ2=0.00 (0.00, 0.47), I 2=0%, 95% PI −1.88, 2.33 | N/A | N/A | N/A | Strong45 46
Weak |
| Burden (n=3)41 43 48 | d=0.04 (95% CI −1.94, 2.01, p=0.94) | τ2=0.57 (0.12, 25.86), I 2=91.9%, 95% PI=−11.16, 11.23 | N/A | N/A | N/A | Moderate41 43 48 |
| Burden within-group only (n=2)43 48 | d_av=−0.41 (95% CI −1.78, 0.96, p=0.16) | τ2=0.01, I 2=48.3% | N/A | N/A | N/A | Moderate43 48 |
| Self-efficacy (n=3)43 46 51 | d=0.69 (95% CI −0.72, 2.10, p=0.17) | τ2=0.26, I 2=82.4%, 95% PI=−7.10, 8.45 | N/A | N/A | N/A | Strong46
Moderate43 51 |
| Self-efficacy within-group only (n=2)43 51 | d_av=1.05 (95% CI −1.02, 3.13, p=0.10) | τ2=0.02, I 2=15.6% | N/A | N/A | N/A | Moderate43 51 |
| Quality of life (n=2)38 42 | d=0.67 (95% CI −9.99, 11.34, p=0.57) | τ2=1.33, I 2=94% | N/A | N/A | N/A | Moderate38
Weak42 |
| Knowledge of mood disorders (n=2)40 49 | d=0.80 (95% CI −2.04, 3.64, p=0.17) | τ2=0.02, I 2=17.6% | N/A | N/A | N/A | Moderate40 49 |
| Follow-up effects | ||||||
| Anxiety (n=3)39 44 45 | d=−0.56 (95% CI −1.46, 0.34, p=0.12) | τ2=<0.001 (95% CI 0.00, 14.14), I 2=0%, 95% PI=−3.43, 2.31 | N/A | N/A | N/A | Strong44 45
Moderate39 |
| Depression (n=3)41 45 48 | d=0.08 (95% CI −1.43, 1.59, p=0.85) | τ2=0.30 (95% CI 0.03, 15.58), I 2=81.7%, 95% PI=8.08, 8.24 | N/A | N/A | N/A | Strong45
Moderate41 48 |
| Depression between-group only (n=2)41 45 | g=0.18 (95% −7.57, 7.93, p=0.82) | τ2=0.68, I 2=90.2% | N/A | N/A | N/A | Strong45
Moderate41 |
| Knowledge of mood disorders (n=2)40 49 | d=0.30 (95% CI −2.12, 2.72, p=0.36) | τ2=0.00, I 2=0% | N/A | N/A | N/A | Moderate40 49 |
EPHPP, Effective Public Health Practice Project; N, no; N/A, not applicable; Y, yes.